Regeneron Pharmaceuticals (REGN) EBITDA Margin (2009 - 2026)
Regeneron Pharmaceuticals' quarterly EBITDA Margin came in at 18.35% in Q1 2026, down 957.0% year-on-year from 2.14% in Q1 2025, and down 16.45% quarter-over-quarter from 21.96% in Q4 2025.
Regeneron Pharmaceuticals has reported EBITDA Margin for 18 years, with the latest figure at 18.35% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 957.0% year-over-year to 18.35%; the trailing twelve-month figure through Mar 2026 stood at 29.53% (down 316.0% YoY), and the FY2025 full-year result was 32.0%, up 42.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 18.35%, down from 21.96% in the prior quarter.
- The five-year high for EBITDA Margin was 1659.2% in Q1 2022, with the low at 18.35% in Q1 2026.
- Average EBITDA Margin over 5 years is 197.66%, with a median of 30.59% recorded in 2023.
- Year-over-year, EBITDA Margin soared 161562 bps in 2022 and plunged 163153 bps in 2023.
- Tracing REGN's EBITDA Margin over 5 years: stood at 1233.4% in 2022, then tumbled by 97 bps to 36.56% in 2023, then tumbled by 39 bps to 22.42% in 2024, then decreased by 2 bps to 21.96% in 2025, then dropped by 16 bps to 18.35% in 2026.
- The last three EBITDA Margin figures came in at 18.35% (Q1 2026), 21.96% (Q4 2025), and 39.33% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.35% |
| Dec 31, 2025 | 21.96% |
| Sep 30, 2025 | 39.33% |
| Jun 30, 2025 | 38.50% |
| Mar 31, 2025 | 27.92% |
| Dec 31, 2024 | 22.42% |
| Sep 30, 2024 | 39.53% |
| Jun 30, 2024 | 40.59% |
| Mar 31, 2024 | 23.07% |
| Dec 31, 2023 | 36.56% |
| Sep 30, 2023 | 30.59% |
| Jun 30, 2023 | 30.15% |
| Mar 31, 2023 | 27.67% |
| Dec 31, 2022 | 1,233.40% |
| Sep 30, 2022 | 43.06% |
| Jun 30, 2022 | 27.94% |
| Mar 31, 2022 | 1,659.20% |
| Dec 31, 2021 | 44.29% |
| Sep 30, 2021 | 47.09% |
| Jun 30, 2021 | 60.30% |
| Mar 31, 2021 | 43.58% |
| Dec 31, 2020 | 47.37% |
| Sep 30, 2020 | 36.50% |
| Jun 30, 2020 | 48.25% |
| Mar 31, 2020 | 32.51% |
| Dec 31, 2019 | 42.75% |
| Sep 30, 2019 | 38.44% |
| Jun 30, 2019 | 13.06% |
| Mar 31, 2019 | 34.69% |
| Dec 31, 2018 | 42.46% |
| Sep 30, 2018 | 35.81% |
| Jun 30, 2018 | 34.54% |
| Mar 31, 2018 | 30.98% |
| Dec 31, 2017 | 9.50% |
| Sep 30, 2017 | 27.31% |
| Jun 30, 2017 | 26.94% |
| Mar 31, 2017 | 19.40% |
| Dec 31, 2016 | 19.82% |
| Sep 30, 2016 | 21.04% |
| Jun 30, 2016 | 16.25% |
| Mar 31, 2016 | 14.75% |
| Dec 31, 2015 | 14.19% |
| Sep 30, 2015 | 17.49% |
| Jun 30, 2015 | 16.61% |
| Mar 31, 2015 | 8.24% |
| Dec 31, 2014 | 14.39% |
| Sep 30, 2014 | 14.61% |
| Jun 30, 2014 | 14.89% |
| Mar 31, 2014 | 11.34% |
| Dec 31, 2013 | 14.39% |
| Sep 30, 2013 | 23.77% |
| Jun 30, 2013 | 18.70% |
| Mar 31, 2013 | 22.38% |
| Dec 31, 2012 | 113.64% |
| Sep 30, 2012 | 44.88% |
| Jun 30, 2012 | 24.87% |
| Mar 31, 2012 | 5.25% |
| Dec 31, 2011 | -43.56% |
| Sep 30, 2011 | -61.45% |
| Jun 30, 2011 | -56.80% |
| Mar 31, 2011 | -38.44% |
| Dec 31, 2010 | 97.98% |
| Sep 30, 2010 | -650.20% |
| Jun 30, 2010 | -20.47% |
| Mar 31, 2010 | -1,531.12% |
| Dec 31, 2009 | -300.02% |
| Sep 30, 2009 | -1.10% |
| Jun 30, 2009 | -361.47% |